Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic Diseases

Fernando F Anhê; Benjamin A H Jensen; Lais Rossi Perazza; André Tchernof; Jonathan D Schertzer; André Marette

doi:10.12997/jla.2021.10.2.123

Bacterial Postbiotics as Promising Tools to Mitigate Cardiometabolic Diseases

J Lipid Atheroscler. 2021 May;10(2):123-129. doi: 10.12997/jla.2021.10.2.123. Epub 2021 Feb 9.

Authors

Fernando F Anhê^{1

2

3}, Benjamin A H Jensen⁴, Lais Rossi Perazza⁵, André Tchernof⁵, Jonathan D Schertzer^{1

2

3}, André Marette⁵

Affiliations

¹ Department of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
² Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
³ Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada.
⁴ Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁵ Quebec Heart and Lung Research Institute, Laval University, Quebec, Canada.

Abstract

Gut microbes dictate critical features of host immunometabolism. Certain bacterial components and metabolites (termed postbiotics) mitigate cardiometabolic diseases whereas others potentiate pathological processes. In this review, we discuss key aspects related to the usefulness of bacterial-related molecules strategically positioned as promising treatment strategies for cardiometabolic diseases.

Keywords: Akkermansia; Diabetes mellitus, type 2; Lipopolysaccharides; Obesity; Peptidoglycan.